Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123618 | 0.95 | L3MBTL1 (0.37) | METAP2ALDH1A1CTSKNPSR1TSHR | |
| SCHEMBL28872183 | 0.91 | L3MBTL1 (0.39) | ALDH1A1NPSR1L3MBTL1CYP2D6 | |
| SCHEMBL11378743 | 0.91 | L3MBTL1 (0.39) | ALDH1A1NPSR1L3MBTL1CYP2D6 | |
| SCHEMBL27939505 | 0.85 | CTSK (0.37) | METAP2ALDH1A1CTSKNPSR1THRB | |
| SCHEMBL1008531 | 0.84 | CTSK (0.42) | CTSKNPSR1TSHR | |
| SCHEMBL14386506 | 0.83 | CPN1 (0.42) | L3MBTL1 | |
| SCHEMBL2297433 | 0.83 | ALDH1A1 (0.41) | ALDH1A1NPSR1TSHRL3MBTL1 | |
| SCHEMBL4425794 | 0.81 | METAP2 (0.43) | METAP2ALDH1A1CTSKNPSR1TSHR | |
| SCHEMBL1008660 | 0.81 | ZDHHC7 (0.42) | CTSKNPSR1TSHRTHRB | |
| SCHEMBL1009433 | 0.81 | ZDHHC7 (0.42) | CTSKNPSR1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1631296-B1 | 2,3,4,5-TETRAHYDROBENZO¬F|¬1,4|OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | HOFFMANN LA ROCHE (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-7060698-B2 | Benzoxazepinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1631296-A1 | 2,3,4,5-TETRAHYDROBENZO[F][1,4]OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004100958-A1 | 2, 3, 4, 5-TETRAHYDROBENZO[F][1, 4]OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | HOFFMANN-LA ROCHE INC. | 2004-11-25 | — | — | US | disclosed |
| EP-0703919-B1 | PHOSPHOSUCCINIC ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1998-09-02 | — | — | EP | disclosed |
| US-5683994-A | BONE DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0703919-A1 | PHOSPHOSUCCINIC ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS | Roche Diagnostics GmbH (DE) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995000522-A1 | PHOSPHOSUCCINIC ACID DERIVATIVES AND THEIR USE AS MEDICAMENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | BACE1, BACE2, PSEN1 | METAP2 1934/4885ALDH1A1 724/4885CTSK 1368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.